BioMed Research International

Basic and Translational Advances in Glioblastoma


Status
Published

1UT Southwestern Medical Center, Dallas, USA

2University Hospital of Navarra, Pamplona, Spain

3Pisa University Hospital, Pisa, Italy


Basic and Translational Advances in Glioblastoma

Description

Glioblastoma is diagnosed using histopathological features and includes multiple variants. In the last years, the advent of next generation sequencing technologies has allowed the interrogation of the genetic landscape of glioblastoma at high resolution. As a result, cellular and molecular heterogeneity have been described among patients. This represents a milestone in glioblastoma research, although clinical applications for the benefit of patients are yet to come.

Due to the high degree of heterogeneity, little is known about the molecular events underpinning the genesis of glioblastoma and the disease is already advanced at clinical presentation, thus complicating the efficacy of therapies.

This special issue is intended to focus on novel basic and translational advances in glioblastoma research which are expected to impact on patient treatment and improve survival.

Potential topics include but are not limited to the following:

  • Novel therapeutic approaches targeting tumour-initiating cells
  • The impact of intratumour heterogeneity on therapy resistance
  • Molecular mechanisms of tumour growth and invasion
  • Evolutionary dynamics after therapy
  • Advances in tumour sampling and circulating tumour cells and cell-free DNA
  • Novel in vitro and in vivo models for drug screening
  • Improving the molecular-based and imaging-based proposed classifications of glioblastoma
  • Cell of origin and tumour-initiating cells

Articles

  • Special Issue
  • - Volume 2018
  • - Article ID 1820345
  • - Editorial

Basic and Translational Advances in Glioblastoma

Sara G. M. Piccirillo | Marta M. Alonso | Francesco Pasqualetti
  • Special Issue
  • - Volume 2018
  • - Article ID 4010629
  • - Review Article

Therapeutic Potential of Thymoquinone in Glioblastoma Treatment: Targeting Major Gliomagenesis Signaling Pathways

Fabliha Ahmed Chowdhury | Md Kamal Hossain | ... | Muhammad Shahdaat Bin Sayeed
  • Special Issue
  • - Volume 2017
  • - Article ID 2690187
  • - Research Article

Failure of the PTEN/aPKC/Lgl Axis Primes Formation of Adult Brain Tumours in Drosophila

Simona Paglia | Manuela Sollazzo | ... | Daniela Grifoni
  • Special Issue
  • - Volume 2017
  • - Article ID 9363040
  • - Review Article

Natural Bioactive Compounds: Alternative Approach to the Treatment of Glioblastoma Multiforme

Vilas Desai | Alok Bhushan
  • Special Issue
  • - Volume 2017
  • - Article ID 7082696
  • - Review Article

mTOR-Dependent Cell Proliferation in the Brain

Larisa Ryskalin | Gloria Lazzeri | ... | Francesco Fornai
  • Special Issue
  • - Volume 2017
  • - Article ID 7403747
  • - Review Article

Apoptotic Signaling Pathways in Glioblastoma and Therapeutic Implications

Silvia Anahi Valdés-Rives | Diana Casique-Aguirre | ... | Aliesha González-Arenas
  • Special Issue
  • - Volume 2017
  • - Article ID 8569328
  • - Research Article

In Vitro/In Silico Study on the Role of Doubling Time Heterogeneity among Primary Glioblastoma Cell Lines

M.-E. Oraiopoulou | E. Tzamali | ... | V. Sakkalis
  • Special Issue
  • - Volume 2017
  • - Article ID 8139848
  • - Review Article

Review of Natural Product-Derived Compounds as Potent Antiglioblastoma Drugs

Moon Nyeo Park | Hyo Sook Song | ... | Bonglee Kim
  • Special Issue
  • - Volume 2017
  • - Article ID 7218707
  • - Research Article

High-Dose Compound Heat Map for 3D-Cultured Glioblastoma Multiforme Cells in a Micropillar and Microwell Chip Platform

Dong Woo Lee | Sang-Yun Lee | ... | Do-Hyun Nam
  • Special Issue
  • - Volume 2017
  • - Article ID 9157370
  • - Review Article

MicroRNA Regulation of Glycolytic Metabolism in Glioblastoma

Huda Alfardus | Alan McIntyre | Stuart Smith
BioMed Research International
 Journal metrics
Acceptance rate31%
Submission to final decision67 days
Acceptance to publication30 days
CiteScore3.600
Impact Factor2.276
 Submit